Cybin

Cybin Reports Positive Topline Data From Phase 2 Study Of CYB003 in Major Depressive Disorder

Nov 30, 2023

Doug Drysdale On Cybin, Mental Health, And CYB003 Results

Nov 3, 2023

Cybin Phase 2 Major Depressive Disorder Study Demonstrates Rapid and Remarkable Outcomes

Oct 31, 2023

Financial Giants And The NRA Are Lobbying For Banking Reform

Oct 30, 2023

CEO Doug Drysdale Explains Cybin Patent Approvals

Oct 27, 2023

Cybin Becomes Foremost Leader In DMT Research With Closing Of Small Pharma Acquisition

Oct 23, 2023

Cybin Closing Of Small Pharma Acquisition Imminent As Final Arrangement Order Obtained

Oct 19, 2023

Cybin Completes Phase 2 Dosing Study For Major Depressive Disorder

Oct 3, 2023

Small Pharma: Positive Top-line Data from SPL026 SSRI Drug Interaction Study

Sep 26, 2023

Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression 

Sep 22, 2023